These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23681900)

  • 1. CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.
    Cheng Y; Tao L; Xu J; Li Q; Yu J; Jin Y; Chen Q; Xu Z; Zou Q; Liu X
    Mol Carcinog; 2014 Sep; 53(9):686-97. PubMed ID: 23681900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.
    Litviakov NV; Cherdyntseva NV; Tsyganov MM; Slonimskaya EM; Ibragimova MK; Kazantseva PV; Kzhyshkowska J; Choinzonov EL
    Oncotarget; 2016 Feb; 7(7):7829-41. PubMed ID: 26799285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.
    Soon PS; Kim E; Pon CK; Gill AJ; Moore K; Spillane AJ; Benn DE; Baxter RC
    Endocr Relat Cancer; 2013 Feb; 20(1):1-12. PubMed ID: 23111755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response.
    Litviakov NV; Cherdyntseva NV; Tsyganov MM; Denisov EV; Garbukov EY; Merzliakova MK; Volkomorov VV; Vtorushin SV; Zavyalova MV; Slonimskaya EM; Perelmuter VM
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):153-63. PubMed ID: 23053273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells.
    Xu JW; Li QQ; Tao LL; Cheng YY; Yu J; Chen Q; Liu XP; Xu ZD
    Int J Oncol; 2011 Dec; 39(6):1501-9. PubMed ID: 21805028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells.
    Droeser RA; Obermann EC; Wolf AM; Wallner S; Wolf D; Tzankov A
    Clin Breast Cancer; 2013 Aug; 13(4):264-70. PubMed ID: 23829892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
    Gudadze M; Kankava Q; Mariamidze A; Burkadze G
    Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAM-A expression positively correlates with poor prognosis in breast cancer patients.
    McSherry EA; McGee SF; Jirstrom K; Doyle EM; Brennan DJ; Landberg G; Dervan PA; Hopkins AM; Gallagher WM
    Int J Cancer; 2009 Sep; 125(6):1343-51. PubMed ID: 19533747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
    Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
    Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
    Noske A; Loibl S; Darb-Esfahani S; Roller M; Kronenwett R; Müller BM; Steffen J; von Toerne C; Wirtz R; Baumann I; Hoffmann G; Heinrich G; Grasshoff ST; Ulmer HU; Denkert C; von Minckwitz G
    Breast Cancer Res Treat; 2011 Feb; 126(1):109-17. PubMed ID: 21190079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer.
    Loh TJ; Moon H; Cho S; Jang H; Liu YC; Tai H; Jung DW; Williams DR; Kim HR; Shin MG; Liao DJ; Zhou J; Shi W; Zheng X; Shen H
    Oncol Rep; 2015 Sep; 34(3):1231-8. PubMed ID: 26151392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
    Bonneterre J; Révillion F; Desauw C; Blot E; Kramar A; Fournier C; Hornez L; Peyrat JP
    Oncol Rep; 2013 Jan; 29(1):355-61. PubMed ID: 23117275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
    Mylona E; Giannopoulou I; Fasomytakis E; Nomikos A; Magkou C; Bakarakos P; Nakopoulou L
    Hum Pathol; 2008 Jul; 39(7):1096-102. PubMed ID: 18495204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of angio-associated migratory cell protein (AAMP) on breast cancer cells in vitro and its clinical significance.
    Yin Y; Sanders AJ; Jiang WG
    Anticancer Res; 2013 Apr; 33(4):1499-509. PubMed ID: 23564791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
    Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
    Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
    Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
    Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.